Danese MD, Griffiths RI, Gleeson ML, et al. Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy. Leuk Lymphoma. http://dx.doi.org/10.1080/10428194.2016.1228924
The authors of the above article wish to advise that the artwork for Figure 2 was duplicated and published in place of . The correct is reproduced below.
Figure 1. Overall, unadjusted Kaplan–Meier survival estimates for relapsed patients. Unadjusted Kaplan–Meier survival curves over time. Patients were stratified by the use of rituximab in first line, rituximab use in second line, the three types of therapy, gender, B-symptoms, and anemia. See ‘Supplementary Materials’ for lists of the types of therapy within each type.
